{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:19:36Z","timestamp":1787588376463,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:00:00Z","timestamp":1598313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:00:00Z","timestamp":1598313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s11910-020-01064-0","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T02:02:22Z","timestamp":1598320942000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Neuromuscular Complications of Statin Therapy"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6090-8956","authenticated-orcid":false,"given":"Elena","family":"Crisan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya K.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,25]]},"reference":[{"issue":"3","key":"1064_CR1","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jacl.2019.04.011","volume":"13","author":"TA Jacobson","year":"2019","unstructured":"Jacobson TA, Cheeley MK, Jones PH, La Forge R, Maki KC, L\u00f3pez JAG, et al. The STatin adverse treatment experience survey: experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019;13(3):415\u201324.","journal-title":"J Clin Lipidol"},{"key":"1064_CR2","doi-asserted-by":"crossref","unstructured":"Serban M-C, Colantonio LD, Manthripragada AD, Monda KL, Bittner VA, Banach M, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. 2017.","DOI":"10.1016\/j.jacc.2016.12.036"},{"issue":"6","key":"1064_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E Bruckert","year":"2005","unstructured":"Bruckert E, Hayem G, Dejager S, Yau C, B\u00e9gaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403\u201314.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1064_CR4","doi-asserted-by":"crossref","unstructured":"Ganga H V., Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Vol. 168, American Heart Journal. Mosby Inc.; 2014. p. 6\u201315.","DOI":"10.1016\/j.ahj.2014.03.019"},{"key":"1064_CR5","doi-asserted-by":"crossref","unstructured":"Hilton-Jones D. Statin-related myopathies. Vol. 18, Practical Neurology. BMJ Publishing Group; 2018. p. 97\u2013105.","DOI":"10.1136\/practneurol-2017-001738"},{"issue":"1","key":"1064_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3949\/ccjm.83a.14120","volume":"83","author":"S Moghadam-Kia","year":"2016","unstructured":"Moghadam-Kia S, Oddis CV, Aggarwal R. Approach to asymptomatic creatine kinase elevation. Cleve Clin J Med. 2016;83(1):37\u201342.","journal-title":"Cleve Clin J Med"},{"key":"1064_CR7","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.cjca.2013.09.023","volume":"29","author":"GBJ Mancini","year":"2013","unstructured":"Mancini GBJ, Tashakkor AY, Baker S, Bergeron J, Fitchett D, Frohlich J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian working group consensus update. Canadian Journal of Cardiology. 2013;29:1553\u201368.","journal-title":"Canadian Journal of Cardiology"},{"issue":"6","key":"1064_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1592\/phco.30.6.541","volume":"30","author":"S Cham","year":"2010","unstructured":"Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy. 2010;30(6):541\u201353.","journal-title":"Pharmacotherapy."},{"key":"1064_CR9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/BOR.0b013e32833f0fc7","volume":"22","author":"AL Mammen","year":"2010","unstructured":"Mammen AL, Amato AA. Statin myopathy: a review of recent progress. Current Opinion in Rheumatology. 2010;22:644\u201350.","journal-title":"Current Opinion in Rheumatology"},{"issue":"10","key":"1064_CR10","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1345\/aph.1G035","volume":"39","author":"J Chan","year":"2005","unstructured":"Chan J, Hui RL, Levin E. Differential association between statin exposure and elevated levels of creatine kinase. Ann Pharmacother. 2005;39(10):1611\u20136.","journal-title":"Ann Pharmacother"},{"key":"1064_CR11","doi-asserted-by":"crossref","unstructured":"\u2022 Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. An assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol. 2014;8(3 SUPPL). Important for clasification and terminology of statin-associated muscle adverse events.","DOI":"10.1016\/j.jacl.2014.03.004"},{"key":"1064_CR12","doi-asserted-by":"crossref","unstructured":"Franc S, Dejager S, Bruckert E, Chauvenet M, Giral P, Turpin G. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Vol. 17, Cardiovascular Drugs and Therapy. Kluwer Academic Publishers; 2003.","DOI":"10.1023\/B:CARD.0000015861.26111.ab"},{"key":"1064_CR13","doi-asserted-by":"crossref","unstructured":"\u2022 Doughty CT, Amato AA. Toxic myopathies [Internet]. Vol. 25, CONTINUUM Lifelong learning in neurology. 2019. p. 1712\u201331. Available from: https:\/\/journals.lww.com\/continuum. Important up to date neurology review on toxic myopathies, including statins muscle toxicity.","DOI":"10.1212\/CON.0000000000000806"},{"key":"1064_CR14","doi-asserted-by":"crossref","unstructured":"Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, Lois M, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA [Internet]. 2004;292:2585\u201390. Available from: https:\/\/jamanetwork.com\/","DOI":"10.1001\/jama.292.21.2585"},{"key":"1064_CR15","doi-asserted-by":"crossref","unstructured":"Allenbach Y, Mammen AL, Benveniste O, Stenzel W, Allenbach Y, Amato A, et al. 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016. In: Neuromuscular Disorders. Elsevier Ltd; 2018. p. 87\u201399.","DOI":"10.1016\/j.nmd.2017.09.016"},{"key":"1064_CR16","doi-asserted-by":"crossref","unstructured":"Selva-O\u2019callaghan A, Pinal-Fernandez I, Trallero-Aragu\u00e1s E, Milisenda JC, Grau-Junyent M, Mammen AL. Classification and management of adult inflammatory myopathies [Internet]. Vol. 17. 2018. Available from: www.thelancet.com\/neurology","DOI":"10.1016\/S1474-4422(18)30254-0"},{"key":"1064_CR17","unstructured":"\u2022\u2022 Goyal NA. Immune-mediated myopathies. 2019. Important up to date neurology review on inflamatory myopathies and statin-induced anti HMG CoA reductase myopathy subtype."},{"key":"1064_CR18","doi-asserted-by":"crossref","unstructured":"Ohnuki Y, Suzuki S, Shiina T, Uruha A, Watanabe Y, Suzuki S, et al. Clinical\/scientific notes HLA-DRB1 alleles in immune-mediated necrotizing myopathy. 2016.","DOI":"10.1212\/WNL.0000000000003160"},{"key":"1064_CR19","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Allenbach Y, Keraen J, Bouvier AM, Jooste V, Champtiaux N, Hervier B, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain. 2016;139(8):2131\u20135. Important up to date neurology review on inflamatory myopathies and statin-induced anti HMG CoA reductase myopathy subtype.","DOI":"10.1093\/brain\/aww054"},{"key":"1064_CR20","doi-asserted-by":"crossref","unstructured":"Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA [Internet]. 2003;289:1681\u201390. Available from: https:\/\/jamanetwork.com\/","DOI":"10.1001\/jama.289.13.1681"},{"issue":"3","key":"1064_CR21","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1365-2125.2011.03996.x","volume":"72","author":"P Reddy","year":"2011","unstructured":"Reddy P, Ellington D, Zhu Y, Zdrojewski I, Parent SJ, Harmatz JS, et al. Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. Br J Clin Pharmacol. 2011 Sep;72(3):434\u201341.","journal-title":"Br J Clin Pharmacol"},{"key":"1064_CR22","doi-asserted-by":"crossref","unstructured":"Rosenson RS, Colantonio LD, Burkholder GA, Chen L, Muntner P. Trends in utilization of statin therapy and contraindicated statin use in HIV-infected adults treated with antiretroviral therapy from 2007 through 2015. J Am Heart Assoc 2018 1;7(24).","DOI":"10.1161\/JAHA.118.010345"},{"issue":"6","key":"1064_CR23","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/mus.20135","volume":"30","author":"SK Baker","year":"2004","unstructured":"Baker SK, Goodwin S, Sur M, Tarnopolsky MA. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve. 2004 Dec;30(6):799\u2013802.","journal-title":"Muscle Nerve"},{"key":"1064_CR24","doi-asserted-by":"crossref","unstructured":"Evans M, Rees A. The myotoxicity of statins. 2002.","DOI":"10.1097\/00041433-200208000-00009"},{"key":"1064_CR25","doi-asserted-by":"crossref","unstructured":"Rosenson RS, Baker S, Banach M, Borow KM, Braun LT, Bruckert E, et al. Optimizing cholesterol treatment in patients with muscle complaints. 2017.","DOI":"10.1016\/j.jacc.2017.07.752"},{"key":"1064_CR26","doi-asserted-by":"crossref","unstructured":"Nguyen KA, Li L, Lu D, Yazdanparast A, Wang L, Kreutz RP, et al. A comprehensive review and meta-analysis of risk factors for statin-induced myopathy. Vol. 74, European Journal of Clinical Pharmacology. Springer Verlag; 2018. p. 1099\u2013109.","DOI":"10.1007\/s00228-018-2482-9"},{"key":"1064_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijcard.2014.10.118","volume":"178","author":"M Michalska-Kasiczak","year":"2015","unstructured":"Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, Rysz J, Muntner P, Toth PP, et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia\u2014a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol. 2015;178:111\u20136.","journal-title":"Int J Cardiol"},{"key":"1064_CR28","first-page":"56","volume":"6","author":"KD Riche","year":"2016","unstructured":"Riche KD, Arnall J, Rieser K, East HE, Riche DM. Impact of vitamin D status on statin-induced myopathy. J Clin Transl Endocrinol. 2016;6:56\u20139.","journal-title":"J Clin Transl Endocrinol"},{"issue":"5","key":"1064_CR29","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1177\/0897190016674407","volume":"30","author":"JH Kang","year":"2017","unstructured":"Kang JH, Nguyen QN, Mutka J, Le QA. Rechallenging statin therapy in veterans with statin-induced myopathy post vitamin D replenishment. J Pharm Pract. 2017;30(5):521\u20137.","journal-title":"J Pharm Pract"},{"issue":"8","key":"1064_CR30","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"T Meade","year":"2008","unstructured":"Meade T, Sleight P, Collins R, Armitage J, Parish S, Barton J, et al. SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study. N Engl J Med. 2008;359(8):789\u201399.","journal-title":"N Engl J Med"},{"key":"1064_CR31","doi-asserted-by":"crossref","unstructured":"Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. Vol. 42, Muscle and Nerve. John Wiley and Sons Inc.; 2010. p. 469\u201379.","DOI":"10.1002\/mus.21817"},{"issue":"2","key":"1064_CR32","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.amjcard.2011.08.045","volume":"109","author":"BA Parker","year":"2012","unstructured":"Parker BA, Augeri AL, Capizzi JA, Ballard KD, Troyanos C, Baggish AL, et al. Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol. 2012;109(2):282\u20137.","journal-title":"Am J Cardiol"},{"issue":"3","key":"1064_CR33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/mus.23309","volume":"46","author":"J Bouitbir","year":"2012","unstructured":"Bouitbir J, Daussin F, Charles AL, Rasseneur L, Dufour S, Richard R, et al. Mitochondria of trained skeletal muscle are protected from deleterious effects of statins. Muscle Nerve. 2012;46(3):367\u201373.","journal-title":"Muscle Nerve"},{"issue":"1","key":"1064_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.amjmed.2008.08.033","volume":"122","author":"RC Neal","year":"2009","unstructured":"Neal RC, Ferdinand KC, Y\u010das J, Miller E. Relationship of ethnic origin, gender, and age to blood creatine kinase levels. Am J Med. 2009;122(1):73\u20138.","journal-title":"Am J Med"},{"issue":"6","key":"1064_CR35","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1001\/archinte.163.6.688","volume":"163","author":"CC Smith","year":"2003","unstructured":"Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med [Internet]. 2003;163(6):688\u201392 Available from: https:\/\/jamanetwork.com\/.","journal-title":"Arch Intern Med [Internet]"},{"key":"1064_CR36","doi-asserted-by":"crossref","unstructured":"Meriggioli M, Barboi A, Rowin J, Cochran E. HMG-CoA reductase inhibitor myopathy: clinical, electrophysiological, and pathologic data in five patients. J Clin Neuromuscul Dis. 2001;3 Number 3:129\u201334.","DOI":"10.1097\/00131402-200103000-00003"},{"issue":"2","key":"1064_CR37","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/acr.20662","volume":"64","author":"AL Mammen","year":"2012","unstructured":"Mammen AL, Pak K, Williams EK, Brisson D, Coresh J, Selvin E, et al. Rarity of anti-3-hydroxy-3-Methylglutaryl-coenzyme a reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res. 2012;64(2):269\u201372.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"1064_CR38","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/mus.25127","volume":"54","author":"JS Floyd","year":"2016","unstructured":"Floyd JS, Brody JA, Tiniakou E, Psaty BM, Mammen A. Absence of anti\u2013HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy. Muscle Nerve. 2016;54(1):142\u20134.","journal-title":"Muscle Nerve"},{"issue":"12","key":"1064_CR39","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1002\/art.34673","volume":"64","author":"JL Werner","year":"2012","unstructured":"Werner JL, Christopher-Stine L, Ghazarian SR, Pak KS, Kus JE, Daya NR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum. 2012;64(12):4087\u201393.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1064_CR40","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1136\/annrheumdis-2016-210198","volume":"76","author":"I Pinal-Fernandez","year":"2017","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, Lahouti AH, Basharat P, Albayda J, et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis. 2017;76(4):681\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1064_CR41","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/mus.26637","volume":"60","author":"V Gras-Champel","year":"2019","unstructured":"Gras-Champel V, Batteux B, Masmoudi K, Liabeuf S. Statin-induced myasthenia: a disproportionality analysis of the WHO\u2019s VigiBase pharmacovigilance database. Muscle Nerve. 2019;60(4):382\u20136.","journal-title":"Muscle Nerve"},{"key":"1064_CR42","doi-asserted-by":"crossref","unstructured":"Gale J, Danesh-Meyer H V. Statins can induce myasthenia gravis. Vol. 21, Journal of Clinical Neuroscience. Churchill Livingstone; 2014. p. 195\u20137.","DOI":"10.1016\/j.jocn.2013.11.009"},{"key":"1064_CR43","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/mus.21074","volume":"38","author":"S Oh","year":"2008","unstructured":"Oh S, Dhall R, Young A, Morgan M, Lu L, Claussen G, et al. Statins may aggravate myasthenia gravis. Muscle Nerve. 2008;38:1101\u20137.","journal-title":"Muscle Nerve"},{"key":"1064_CR44","doi-asserted-by":"crossref","unstructured":"Purvin V, Kawasaki A, Smith KH, Kesler A. Statin-associated myasthenia gravis: Report of 4 cases and review of the literature. Vol. 85, Medicine. 2006. p. 82\u20135.","DOI":"10.1097\/01.md.0000209337.59874.aa"},{"issue":"4","key":"1064_CR45","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40264-017-0620-4","volume":"41","author":"BA Golomb","year":"2018","unstructured":"Golomb BA, Verden A, Messner AK, Koslik HJ, Hoffman KB. Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA\u2019s adverse event reporting system. Drug Saf. 2018;41(4):403\u201313.","journal-title":"Drug Saf"},{"key":"1064_CR46","doi-asserted-by":"crossref","unstructured":"Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar J-L, Bonnefont-Rousselot D, Bittar R, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis [Internet]. 2008. Available from: www.neurology.org","DOI":"10.1212\/01.wnl.0000285080.70324.27"},{"issue":"6","key":"1064_CR47","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/mus.20127","volume":"30","author":"OM Vasconcelos","year":"2004","unstructured":"Vasconcelos OM, Campbell WW. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve. 2004;30(6):803\u20137.","journal-title":"Muscle Nerve"},{"key":"1064_CR48","doi-asserted-by":"crossref","unstructured":"Noel B, Cerottini J, Panizzon R. Atorvastatin-induced dermatomyositis. Vol. 110, The American Journal of Medicine. 2001. p. 670\u20131.","DOI":"10.1016\/S0002-9343(01)00711-2"},{"key":"1064_CR49","doi-asserted-by":"crossref","unstructured":"Tsivgoulis, G, Spengos, K, Karandreas, N, Panas, M, Kladi, A, Manta P. Presymptomatic neuromuscular disorders disclosed following statin treatment [Internet]. Vol. 166, Arch Intern Med. 2006. Available from: https:\/\/jamanetwork.com\/","DOI":"10.1001\/archinte.166.14.1519"},{"key":"1064_CR50","doi-asserted-by":"crossref","unstructured":"Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, et al. Statin-associated myopathy with normal creatine kinase levels [Internet]. Vol. 137, Ann Internal Medicine. 2002. Available from: www.annals.org","DOI":"10.7326\/0003-4819-137-7-200210010-00009"},{"issue":"4","key":"1064_CR51","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1258\/0004563041201554","volume":"41","author":"C Livingstone","year":"2004","unstructured":"Livingstone C, Al Riyami S, Wilkins P, Ferns GA. McArdle\u2019s disease diagnosed following statin-induced myositis. Ann Clin Biochem. 2004;41(4):338\u201340.","journal-title":"Ann Clin Biochem"},{"key":"1064_CR52","doi-asserted-by":"crossref","unstructured":"Voermans NC, Lammens M, Wevers RA, Hermus AR, Van Engelen BG. Statin-disclosed acid maltase deficiency. Vol. 258, Journal of Internal Medicine. 2005. p. 196\u20137.","DOI":"10.1111\/j.1365-2796.2005.01515.x"},{"issue":"1","key":"1064_CR53","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1017\/S0317167100007630","volume":"35","author":"SK Baker","year":"2008","unstructured":"Baker SK, Vladutiu GD, Peltier WL, Isackson PJ, Tarnopolsky MA. Metabolic myopathies discovered during investigations of statin myopathy. Can J Neurol Sci. 2008;35(1):94\u20137.","journal-title":"Can J Neurol Sci"},{"issue":"4","key":"1064_CR54","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/mus.20575","volume":"34","author":"SK Baker","year":"2006","unstructured":"Baker SK, Tarnopolsky MA. Sporadic rippling muscle disease unmasked by simvastatin. Muscle Nerve. 2006;34(4):478\u201381.","journal-title":"Muscle Nerve"},{"key":"1064_CR55","doi-asserted-by":"crossref","unstructured":"Knoblauch, H, Schoewel, V, Rosada, A, Spuler S. Another side to statin-related side effects. Annals of Internal Medicine 2010. p. 478\u20139.","DOI":"10.7326\/0003-4819-152-7-201004060-00025"},{"issue":"7","key":"1064_CR56","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/00003643-200407000-00013","volume":"21","author":"R Krivosic-Horber","year":"2004","unstructured":"Krivosic-Horber R, Wagner JM, Maurage C. Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment. European Journal of Anaesthesiology. 2004;21(7):572\u20134.","journal-title":"European Journal of Anaesthesiology"},{"key":"1064_CR57","doi-asserted-by":"crossref","unstructured":"\u2022 Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL, Goldstein LB, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):E38\u201381. Most up to date AHA guidelines on statin safety.","DOI":"10.1161\/ATV.0000000000000081"},{"key":"1064_CR58","doi-asserted-by":"crossref","unstructured":"Gaist D, Jeppesen U, Andersen M, Garc\u00eda Rodr\u00edguez L A, Hallas J, Sindrup SH. Articles CME statins and risk of polyneuropathy: a case-control study 2002.","DOI":"10.1212\/WNL.58.9.1333"},{"key":"1064_CR59","doi-asserted-by":"crossref","unstructured":"Svendsen TK, N\u00f8rregaard Hansen P, Garc\u00eda Rodr\u00edguez LA, Andersen L, Hallas J, Sindrup SH, et al. Statins and polyneuropathy revisited: case-control study in Denmark, 1999\u20132013. Br J Clin Pharmacol. 2017;83(9):2087\u201395.","DOI":"10.1111\/bcp.13298"},{"key":"1064_CR60","doi-asserted-by":"publisher","unstructured":"Pergolizzi Jr Peter, Magnusson, Jo Ann, LeQuang, Robin, Razmi, Gianpietro, Zampogna, Robert, Taylor Jr J V, Pergolizzi Jr \u00c1 J A, LeQuang J V, Taylor Jr \u00c1R, Magnusson P, Razmi R, Zampogna G. Statins and neuropathic pain: a narrative review. Pain Ther [Internet]. Available from: https:\/\/doi.org\/10.6084\/m9.figshare.11592000","DOI":"10.6084\/m9.figshare.11592000"},{"key":"1064_CR61","doi-asserted-by":"crossref","unstructured":"Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Vol. 119, American Journal of Medicine. Elsevier Inc.; 2006. p. 400\u20139.","DOI":"10.1016\/j.amjmed.2006.02.007"},{"issue":"6","key":"1064_CR62","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1212\/01.CON.0000511070.50715.ab","volume":"22","author":"AL Mammen","year":"2016","unstructured":"Mammen AL. Autoimmune myopathies. Contin Lifelong Learn Neurol [Internet]. 2016;22(6):1852\u201370 Available from: www.ContinuumJournal.com.","journal-title":"Contin Lifelong Learn Neurol [Internet]"},{"issue":"2","key":"1064_CR63","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.21486","volume":"41","author":"P Grable-Esposito","year":"2010","unstructured":"Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve. 2010;41(2):185\u201390.","journal-title":"Muscle Nerve"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-020-01064-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-020-01064-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-020-01064-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T23:58:02Z","timestamp":1629849482000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-020-01064-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,25]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1064"],"URL":"https:\/\/doi.org\/10.1007\/s11910-020-01064-0","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,25]]},"assertion":[{"value":"25 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"47"}}